Keene & Associates Inc. Raises Stake in Smith & Nephew plc (NYSE:SNN)

Keene & Associates Inc. raised its holdings in Smith & Nephew plc (NYSE:SNN) by 18.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,686 shares of the medical equipment provider’s stock after purchasing an additional 2,111 shares during the quarter. Keene & Associates Inc.’s holdings in Smith & Nephew were worth $336,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Securities Inc. raised its stake in shares of Smith & Nephew by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 691 shares during the last quarter. R Squared Ltd acquired a new position in Smith & Nephew in the 4th quarter valued at $41,000. Hara Capital LLC raised its position in Smith & Nephew by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 1,957 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Smith & Nephew by 31.8% in the 4th quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock worth $73,000 after acquiring an additional 718 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Smith & Nephew by 74.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,025 shares of the medical equipment provider’s stock valued at $94,000 after acquiring an additional 1,290 shares in the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Berenberg Bank downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. StockNews.com downgraded Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.

Smith & Nephew Price Performance

Smith & Nephew stock opened at $25.95 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. Smith & Nephew plc has a 1 year low of $23.65 and a 1 year high of $31.72. The firm has a 50 day moving average price of $25.02 and a 200 day moving average price of $27.37.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.